Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point

Summary

Article discusses Erasca as a potential competitor to Revolution Medicines' daroxonrasib, positioning Erasca's candidate at a more competitive price point. No specific clinical or financial data provided in the headline-only article.